Tag Archives: VKTX

Best Low Price Stocks To Own Right Now

In what would be a blow to American aerospace giant Boeing, Delta Air Lines is set to order around 100 jetliners from European rival Airbus, according to two people familiar with the deal.

Atlanta-based Delta will announce a deal later Wednesday for the Airbus A321neo, the sources said. The agreement with Airbus maker will be accompanied by a planned purchase of Pratt & Whitney engines, they added.

Spokespeople for Delta (DAL)and Airbus declined to comment. Boeing (BA) said it had no comment. Delta’s board of directors is expected to meet Wednesday to vote on the Airbus purchase, the sources said.

Delta had been talking to Boeing about buying around 100 of its 737 Max 10 airliners, a person familiar with the matter said.

The move comes a day after Canada announced plans to ditch a deal with Boeing for new F/A-18 Super Hornets in favor of used fighters from Australia.

Boeing and Delta are embroiled in an ongoing trade dispute over the airline’s purchase of the smaller Canadian Bombardier C Series. Boeing has accused Bombardier of selling the C Series to Delta at unfairly low prices, and the U.S. Commerce Department has recommended a preliminary 300% tariff on the import of the jets. Bombardier and the Canadian government deny any unfair trade practices.

Best Low Price Stocks To Own Right Now: BioScrip, Inc.(BIOS)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on BioScrip (BIOS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Money Morning News Team]

    BioScrip Inc.(Nasdaq: BIOS) provides at-home medical care and services across the United States.

    BIOS’s central profit opportunity is in the rapid growth of the pharmaceutical industry. The pharmaceutical market is currently worth $12 billion and is expected to grow at an annual rate of five to seven percent.

  • [By Shane Hupp]

    BioScrip (NASDAQ: BIOS) and Amedisys Home Health and Hospice Care (NASDAQ:AMED) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, earnings, dividends and risk.

Best Low Price Stocks To Own Right Now: Rockwell Medical Technologies Inc.(RMTI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Zoe's Kitchen, Inc. (NYSE: ZOES) fell 27.8 percent to $10.45 in pre-market trading after the company reported weaker-than-expected earnings for its first quarter. The company also lowered its FY18 sales outlook from $358million-$368 million to $345 million-$352 million.
    Hibbett Sports, Inc. (NASDAQ: HIBB) shares fell 15.6 percent to $24.50 in pre-market trading after the company reported weaker-than-expected results for its first quarter.
    Rockwell Medical, Inc. (NASDAQ: RMTI) fell 15.5 percent to $5.02 in the pre-market trading session after the company disclosed that its President and CEO Robert Chioini was terminated.
    BG Staffing Inc (NYSE: BGSF) shares fell 12.7 percent to $19.00 in pre-market trading after reporting a common stock offering.
    8×8, Inc. (NASDAQ: EGHT) fell 9.3 percent to $20.00 in pre-market trading after reporting downbeat quarterly earnings.
    Asia Pacific Wire & Cable Corporation Limited (NASDAQ: APWC) fell 7.7 percent to $2.35 in pre-market trading after rising 3.88 percent on Thursday.
    Gap, Inc. (NYSE: GPS) shares fell 7.5 percent to $30.49 in pre-market trading after the company posted downbeat earnings for its first quarter on Thursday. Comps were up 1 percent in the quarter.
    California Resources Corporation (NYSE: CRC) fell 6.4 percent to $33.91 in pre-market trading.
    Buckle Inc (NYSE: BKE) fell 4.9 percent to $24.50 in pre-market trading following weak quarterly sales.
    China Rapid Finance Limited (NYSE: XRF) shares fell 4.9 percent to $3.13 in pre-market trading after climbing 11.53 percent on Thursday.
    Ross Stores, Inc. (NASDAQ: ROST) fell 4.8 percent to $78.98 in pre-market trading. Ross Stores reported upbeat earnings for its first quarter, but issued weak forecast for the current quarter.
    Callon Petroleum Company (NYSE: CPE) shares fell 4.7 percent to $11.90 in pre-market trading after the company reported pricing of common

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Rockwell Medical (RMTI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Dynatronics (NASDAQ: DYNT) and Rockwell Medical (NASDAQ:RMTI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends and earnings.

Best Low Price Stocks To Own Right Now: Viking Therapeutics, Inc.(VKTX)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Blink Charging Co. (NASDAQ: BLNK) shares climbed 31.68 percent to close at $7.19 on Wednesday. Blink Charging reported Q1 net income of $2.2 million, versus a year-ago net loss of $3.1 million.
    Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) shares gained 24.15 percent to close at $3.29. Eleven Biotherapeutics posted a Q1 loss of $0.11 per share.
    21Vianet Group, Inc. (NASDAQ: VNET) shares surged 24 percent to close at $6.82.
    Check-Cap Ltd. (NASDAQ: CHEK) gained 20.25 percent to close at $4.87.
    HUYA Inc. (NYSE: HUYA) shares surged 18.42 percent to close at $22.50
    Abaxis, Inc. (NASDAQ: ABAX) rose 16.15 percent to close at $83.34. Zoetis Inc. (NYSE: ZTS) announced plans to acquire Abaxis for $83 per share in cash.
    Pain Therapeutics, Inc. (NASDAQ: PTIE) shares jumped 16.07 percent to close at $10.62.
    Bilibili Inc. (NASDAQ: BILI) rose 16.04 percent to close at $14.11.
    Gemphire Therapeutics Inc. (NASDAQ: GEMP) gained 14.88 percent to close at $6.33.
    Phoenix New Media Limited (NYSE: FENG) rose 13.96 percent to close at $5.55.
    Daqo New Energy Corp. (NYSE: DQ) jumped 13.88 percent to close at $67.27 on Wednesday.
    Sea Limited (NYSE: SE) jumped 12.59 percent to close at $11.98 after reporting Q1 results.
    Viking Therapeutics, Inc. (NASDAQ: VKTX) rose 12.01 percent to close at $5.13.
    Ascena Retail Group, Inc. (NASDAQ: ASNA) gained 11.93 percent to close at $3.19.
    Boot Barn Holdings, Inc. (NYSE: BOOT) climbed 11.66 percent to close at $24.52 on Wednesday after the company reported upbeat results for its fourth quarter and issued strong first-quarter earnings guidance.
    Macy's, Inc. (NYSE: M) rose 10.83 percent to close at $33.17 after the company reported stronger-than-expected results for its first quarter and lifted guidance.
    ChemoCentryx, Inc. (NASDAQ: CCXI) gained 9.36 percent to close at $12.50. Canaccord Genuity initiated coverage on ChemoCentryx with a Buy rating.
    Biolinerx Ltd/S ADR (NASDAQ: BLRX)
  • [By Joseph Griffin]

    Viking Therapeutics (NASDAQ:VKTX) last posted its earnings results on Wednesday, May 9th. The biotechnology company reported ($0.10) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.02. equities research analysts forecast that Viking Therapeutics will post -0.45 earnings per share for the current fiscal year.

  • [By George Budwell]

    Over the past year, for example, gene therapy company uniQure N.V. (NASDAQ:QURE) and endocrine specialist Viking Therapeutics (NASDAQ:VKTX) both saw their shares skyrocket against the backdrop of a fairly weak overall market for biotech. Despite their rapid appreciation, though, these two stocks might still be incredible bargains for investors comfortable with high levels of risk. Here’s why.

  • [By George Budwell]

    Shares of Viking Therapeutics (NASDAQ:VKTX), a clinical-stage biotech developing treatments for endocrine and metabolic disorders,dropped by 30.1% last month,according toS&P Global Market Intelligence. What’s all the fuss about?

  • [By William Romov]

    Currently trading at $4.52 per share, Viking Therapeutics Inc. (Nasdaq: VKTX) develops drugs to treat fatty liver disease and post-hip surgery rehabilitation. It has the highest share price of the penny stocks on our list today.

Top 5 Performing Stocks To Invest In Right Now

The British pound is on a scorching rally, making it the best performing major currency of the year so far.

Badly battered in the aftermath of Britain’s 2016 vote to leave the European Union, the currency has staged a major comeback, and has climbed 6% against the dollar and 3% against the euro this year alone.

The pound is gaining ground despite the fact that Brexit remains full of uncertainties. A trade deal between the United Kingdom and the European Union, its biggest trading partner, is far from certain, meaning the country might still crash out of the bloc without one. That would be disastrous for British companies and the wider economy.

So why the boom in the pound?

Kallum Pickering, senior economist at Berenberg, said that while the United Kingdom is missing out on the current global growth upswing because of Brexit, the economy is still doing much better than investors anticipated after the referendum.

The economy grew by 1.7% in 2017. That was weaker than 2016, but way better than the 1.1% predicted by the International Monetary Fund in the wake of the referendum. (Before the vote in June 2016, the IMF had forecast the United Kingdom to grow by 2.2% in 2017.)

Top 5 Performing Stocks To Invest In Right Now: Avangrid, Inc.(AGR)

Advisors’ Opinion:

  • [By Lisa Levin] Companies Reporting Before The Bell
    Kimberly-Clark Corporation (NYSE: KMB) is expected to report quarterly earnings at $1.71 per share on revenue of $4.60 billion.
    Halliburton Company (NYSE: HAL) is projected to report quarterly earnings at $0.42 per share on revenue of $5.75 billion.
    Lennox International Inc. (NYSE: LII) is estimated to report quarterly earnings at $1.09 per share on revenue of $815.16 million.
    Alaska Air Group, Inc. (NYSE: ALK) is projected to report quarterly loss at $0.12 per share on revenue of $1.82 billion.
    Hasbro, Inc. (NASDAQ: HAS) is expected to report quarterly earnings at $0.35 per share on revenue of $822.15 million.
    Lincoln Electric Holdings, Inc. (NASDAQ: LECO) is projected to report quarterly earnings at $1.08 per share on revenue of $729.83 million.
    Tennant Company (NYSE: TNC) is estimated to report quarterly earnings at $0.15 per share on revenue of $251.93 million.
    FirstEnergy Corp. (NYSE: FE) is projected to report quarterly earnings at $0.67 per share on revenue of $3.43 billion.
    Koninklijke Philips NV (ADR) (NYSE: PHG) is estimated to report earnings for its first quarter.
    Bank of Hawaii Corporation (NYSE: BOH) is expected to report quarterly earnings at $1.23 per share on revenue of $162.39 million.
    Avangrid, Inc. (NYSE: AGR) is projected to report quarterly earnings at $0.79 per share on revenue of $1.72 billion.

     

  • [By Motley Fool Staff]

    Avangrid Inc.(NYSE:AGR) Q1 2018 Earnings Conference CallApril 23, 2018 10:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Top 5 Performing Stocks To Invest In Right Now: Sorrento Therapeutics, Inc.(SRNE)

Advisors’ Opinion:

  • [By ]

    Sorrento Therapeutics (SRNE) : “This is the kind of speculative stock that I like.”

    Geron (GERN) : “Let’s stick with high quality like Thermo Fisher Scientific (TMO) .”

  • [By William Romov]

    San Diego-based Sorrento Therapeutics Inc. (Nasdaq: SRNE) develops drugs to treat certain types of cancer and chronic cancer pain.

    On Jan. 6, company officials will present a new proprietary technology for the treatment of cancer. Analysts are calling this new technology a potential “game-changer.”

  • [By ]

    In the Lightning Round, Cramer was bullish on Spotify (SPOT) , Alkermes (ALKS) , Johnson & Johnson (JNJ) , Thermo Fisher Scientific (TMO) , Sorrento Therapeutics (SRNE) , NVIDIA (NVDA) , Nucor, Eli Lilly (LLY) and Kohlberg Kravis Roberts (KKR) .

Top 5 Performing Stocks To Invest In Right Now: Viking Therapeutics, Inc.(VKTX)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Blink Charging Co. (NASDAQ: BLNK) shares climbed 31.68 percent to close at $7.19 on Wednesday. Blink Charging reported Q1 net income of $2.2 million, versus a year-ago net loss of $3.1 million.
    Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) shares gained 24.15 percent to close at $3.29. Eleven Biotherapeutics posted a Q1 loss of $0.11 per share.
    21Vianet Group, Inc. (NASDAQ: VNET) shares surged 24 percent to close at $6.82.
    Check-Cap Ltd. (NASDAQ: CHEK) gained 20.25 percent to close at $4.87.
    HUYA Inc. (NYSE: HUYA) shares surged 18.42 percent to close at $22.50
    Abaxis, Inc. (NASDAQ: ABAX) rose 16.15 percent to close at $83.34. Zoetis Inc. (NYSE: ZTS) announced plans to acquire Abaxis for $83 per share in cash.
    Pain Therapeutics, Inc. (NASDAQ: PTIE) shares jumped 16.07 percent to close at $10.62.
    Bilibili Inc. (NASDAQ: BILI) rose 16.04 percent to close at $14.11.
    Gemphire Therapeutics Inc. (NASDAQ: GEMP) gained 14.88 percent to close at $6.33.
    Phoenix New Media Limited (NYSE: FENG) rose 13.96 percent to close at $5.55.
    Daqo New Energy Corp. (NYSE: DQ) jumped 13.88 percent to close at $67.27 on Wednesday.
    Sea Limited (NYSE: SE) jumped 12.59 percent to close at $11.98 after reporting Q1 results.
    Viking Therapeutics, Inc. (NASDAQ: VKTX) rose 12.01 percent to close at $5.13.
    Ascena Retail Group, Inc. (NASDAQ: ASNA) gained 11.93 percent to close at $3.19.
    Boot Barn Holdings, Inc. (NYSE: BOOT) climbed 11.66 percent to close at $24.52 on Wednesday after the company reported upbeat results for its fourth quarter and issued strong first-quarter earnings guidance.
    Macy's, Inc. (NYSE: M) rose 10.83 percent to close at $33.17 after the company reported stronger-than-expected results for its first quarter and lifted guidance.
    ChemoCentryx, Inc. (NASDAQ: CCXI) gained 9.36 percent to close at $12.50. Canaccord Genuity initiated coverage on ChemoCentryx with a Buy rating.
    Biolinerx Ltd/S ADR (NASDAQ: BLRX)
  • [By William Romov]

    Currently trading at $4.52 per share, Viking Therapeutics Inc. (Nasdaq: VKTX) develops drugs to treat fatty liver disease and post-hip surgery rehabilitation. It has the highest share price of the penny stocks on our list today.

  • [By George Budwell]

    Shares of Viking Therapeutics (NASDAQ:VKTX), a clinical-stage biotech developing treatments for endocrine and metabolic disorders,dropped by 30.1% last month,according toS&P Global Market Intelligence. What’s all the fuss about?

  • [By George Budwell]

    Over the past year, for example, gene therapy company uniQure N.V. (NASDAQ:QURE) and endocrine specialist Viking Therapeutics (NASDAQ:VKTX) both saw their shares skyrocket against the backdrop of a fairly weak overall market for biotech. Despite their rapid appreciation, though, these two stocks might still be incredible bargains for investors comfortable with high levels of risk. Here’s why.

Top 5 Performing Stocks To Invest In Right Now: iShares Core S&P 500 (IVV)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    The S&P 500 is one of the world's most widely followed equity indexes. There are over $7.8 trillion in global assets benchmarked to the index, according to ProShares data. The world's two largest ETFs, SPY and the iShares Core S&P 500 ETF (NYSE: IVV), track the S&P 500. Those ETFs have about $395 billion in combined assets under management and are the only two ETFs trading in the U.S. with over $100 billion in assets.

Top 5 Performing Stocks To Invest In Right Now: Logitech International S.A.(LOGI)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares jumped 155.56 percent to close at $5.75 on Thursday.
    Inspire Medical Systems, Inc. (NYSE: INSP) shares gained 56.12 percent to close at $24.98. Inspire Medical went public Thursday on the New York Stock Exchange. The company issued 6.75 million shares priced at $16 each.
    Presbia PLC (NASDAQ: LENS) shares rose 53.02 percent to close at $3.55.
    Integrated Media Technology Limited (NASDAQ: IMTE) shares rose 46.29 percent to close at $32.11. The nano-cap low-float stock skyrocketed over 1,300 percent on Wednesday on no company specific news which would support the surge. The move higher is consistent with what was seen in other low-float stocks over the past few months.
    Technical Communications Corporation (NASDAQ: TCCO) climbed 27.78 percent to close at $5.75.
    STAAR Surgical Company (NASDAQ: STAA) shares gained 26.27 percent to close at $21.15 after reporting upbeat Q1 results.
    Sharing Economy International Inc. (NASDAQ: SEII) shares jumped 22.16 percent to close at $4.30 on Thursday after gaining 9.32 percent on Wednesday.
    China Advanced Construction Materials Group, Inc. (NASDAQ: CADC) rose 20.45 percent to close at $2.65 on Thursday.
    YRC Worldwide Inc. (NASDAQ: YRCW) surged 18.36 percent to close at $9.99 following upbeat quarterly earnings.
    MYR Group Inc. (NASDAQ: MYRG) jumped 17.68 percent to close at $35.74 after the company posted strong Q1 earnings.
    Xspand Products Lab Inc (NASDAQ: XSPL) jumped 17.4 percent to close at $5.87. Xspand Products priced its IPO at $5 per share.
    Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose 17.32 percent to close at $14.90. Coherus BioSciences reported resubmission of BLA for CHS-1701.
    Rudolph Technologies, Inc. (NASDAQ: RTEC) shares gained 17.17 percent to close at $31.05 following upbeat quarterly earnings.
    The Meet Group, Inc. (NASDAQ: MEET) gained 16.02 percent to close at $2.68 following Q1 earnings.
    Ca
  • [By Demitrios Kalogeropoulos]

    Below we’ll look at three companies –Amazon.com (NASDAQ:AMZN), Logitech (NASDAQ:LOGI), and Skechers USA (NYSE:SKX)– that grew by at least 400% over that period.

  • [By Lisa Levin] Gainers
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) surged 73.3 percent to $3.90.
    Integrated Media Technology Limited (NASDAQ: IMTE) shares gained 51 percent to $33.1365. The nano-cap low-float stock skyrocketed over 1,300 percent on Wednesday on no company specific news which would support the surge. The move higher is consistent with what was seen in other low-float stocks over the past few months.
    Monaker Group, Inc. (NASDAQ: MKGI) shares jumped 34 percent to $3.00.
    Sharing Economy International Inc. (NASDAQ: SEII) shares rose 28.2 percent to $4.51 after gaining 9.32 percent on Wednesday.
    STAAR Surgical Company (NASDAQ: STAA) shares jumped 27.8 percent to $21.40 after reporting upbeat Q1 results.
    Boxlight Corporation (NASDAQ: BOXL) rose 20.5 percent to $8.920 after climbing 107.87 percent on Wednesday.
    Xspand Products Lab Inc (NASDAQ: XSPL) gained 19.5 percent to $ 5.97. Xspand Products priced its IPO at $5 per share.
    YRC Worldwide Inc. (NASDAQ: YRCW) rose 18.9 percent to $10.035 following upbeat quarterly earnings.
    ENDRA Life Sciences Inc. (NASDAQ: NDRA) gained 18.3 percent to $3.0177. ENDRA Life Sciences is expected to report Q1 results on May 15.
    MYR Group Inc. (NASDAQ: MYRG) rose 18.1 percent to $35.85 after the company posted strong Q1 earnings.
    Rudolph Technologies, Inc. (NASDAQ: RTEC) shares jumped 16 percent to $30.75 following upbeat quarterly earnings.
    TTM Technologies, Inc. (NASDAQ: TTMI) gained 13.7 percent to $16.53 after reporting Q1 results.
    Insight Enterprises, Inc. (NASDAQ: NSIT) shares surged 12 percent to $40.06 following better-than-expected Q1 earnings.
    TreeHouse Foods, Inc. (NYSE: THS) rose 11.8 percent to $40.93 following Q1 results.
    Engility Holdings, Inc. (NYSE: EGL) surged 11.2 percent to $27.36. Engility reported upbeat quarterly earnings.
    Synalloy Corporation (NASDAQ: SYNL) rose 10.7 percent to $19.10 following Q1 results.
    Logitech International S.A. (NASDAQ: LOGI)
  • [By Shane Hupp]

    Mckinley Capital Management LLC Delaware raised its stake in Logitech (NASDAQ:LOGI) by 7.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 30,741 shares of the technology company’s stock after acquiring an additional 2,017 shares during the period. Mckinley Capital Management LLC Delaware’s holdings in Logitech were worth $1,129,000 as of its most recent SEC filing.

  • [By Ethan Ryder]

    Logitech (NASDAQ:LOGI) insider Marcel Stolk sold 60,381 shares of the company’s stock in a transaction that occurred on Monday, May 7th. The stock was sold at an average price of $40.08, for a total value of $2,420,070.48. Following the completion of the transaction, the insider now owns 70,928 shares of the company’s stock, valued at approximately $2,842,794.24. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Top 10 Clean Energy Stocks To Watch For 2018

First it was plane makers in Canada and Europe. Now companies in the United States and Brazil might get hitched.

Plane makers Boeing and Embraer issued a joint statement Thursday confirming the “companies are engaged in discussions regarding a potential combination, the basis of which remains under discussion.”

“There is no guarantee a transaction will result from these discussions. Boeing and Embraer do not intend to make any additional comments regarding these discussions,” according to the statement. Any agreement would be subject to approval by their respective boards, shareholders and the Brazilian Government, the statement added.

The Wall Street Journal first reported that Boeing, the world’s largest maker of planes, and Brazil’s Embraer, the third, had held talks about a possible takeover. But approval by the Brazilian Government remained the largest sticking point.

Shares of Embraer (ERJ) rose more than 28% during trading on Thursday.

Top 10 Clean Energy Stocks To Watch For 2018: Roche Holding AG (RHHBY)

Advisors’ Opinion:

  • [By Keith Speights]

    However, Roche (NASDAQOTH:RHHBY) could beat Corbus to market with Actemra. The drug is already approved for treating rheumatoid arthritis and juvenile idiopathic arthritis. Roche expects to file for approval of Actemra in treating system sclerosis in 2018.

  • [By SEEKINGALPHA.COM]

    In fact, Novartis’ RTH258 will be the fourth drug in the market for the treatment of wet age-related macular degeneration, or AMD, behind Avastin (bevacizumab), from Genentech, a subsidiary of Roche (OTCQX:RHHBY), Eylea and Genentech’s Lucentis (ranibizumab). According to the American Academy of Ophthalmology, or AAO, the differences between the three therapies are considered clinically insignificant by many ophthalmologists. Thus, in our view, RTH258 must be priced somewhere between $1,850 for Eylea, and $1,950 for Lucentis, in order for Novartis to be able to compete.

  • [By Keith Speights]

    Eisai (NASDAQOTH:ESALY), Novo Nordisk (NYSE:NVO), and Roche Holding Ltd. (NASDAQOTH:RHHBY) fit that description well. Each of these companies markets obesity drugs, but each also sells a broad array of other products with multiple pipeline candidates potentially on the way. Here’s why Eisai, Novo Nordisk, and Roche rank as the three best obesity-drug stocks to buy in 2017.

  • [By SEEKINGALPHA.COM]

    Sparks preliminary data demonstrated the efficacy in eliminating bleeding but more importantly, the unknowns and variations pose the huge uncertainties when moving forward. What made this worse is the direct comparison with the competitor in the same conference. BioMarin is establishing its leading position in hemophilia A field. Outside the gene therapy for hemophilia A, the recently approved Hemlibra from Roche (OTCQX:RHHBY) and ongoing Phase 3 Fitusiran from Alnylam (NASDAQ: ALNY) could be the direct competitors in this field. The trailing needs time to catch up.

  • [By SEEKINGALPHA.COM]

    AbbVie (ABBV) reported positive trial data from its phase 3 study of venetoclax in combination with Roches (OTCQX:RHHBY) Rituxan in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and showed the venetoclax combo extended progression-free survival compared to bendamustine + Rituxan. I recently covered AbbVie and its pipeline and argued that AbbVie has little to replace Humira with in that pipeline.

  • [By SEEKINGALPHA.COM]

    Medtronic operates both in the therapeutic and diagnostic medical markets throughout the world; the company’s varied product lines face a vast combination of competitors, ranging from large manufacturers with multiple business lines (exemplified by Johnson & Johnson) to smaller manufacturers offering a limited selection of products, like Insulet (NASDAQ:PODD). Other notable competitors include Abbott Labs (NYSE:ABT), C.R. Bard (NYSE:BCR), Baxter (NYSE:BAX), LivaNova (NASDAQ:LIVN), Roche (OTCQX:RHHBY), DexCom (NASDAQ:DXCM) and Tandem (NASDAQ:TNDM).

Top 10 Clean Energy Stocks To Watch For 2018: Avid Technology Inc.(AVID)

Advisors’ Opinion:

  • [By Lisa Levin]

    Avid Technology, Inc. (NASDAQ: AVID) shares were also up, gaining 24 percent to $5.01 following Q3 results. Avid Technology reported Q3 earnings of $0.00 per share on revenue of $105.26 million.

  • [By Monica Gerson]

    Avid Technology, Inc. (NASDAQ: AVID) is estimated to post its quarterly earnings at $0.36 per share on revenue of $144.02 million.

    Consolidated Water Co. Ltd. (NASDAQ: CWCO) is expected to post its quarterly earnings at $0.11 per share on revenue of $15.15 million.

  • [By Anders Bylund]

    Shares of Avid Technology(NASDAQ:AVID) rose 20.3% in April 2017, according to data from S&P Global Market Intelligence.

    So what

    Last month’s share price surge rested on Avid’s release of a coherent cloud-based media production suite. The new version of Avid’s MediaCentral platform takes advantage of the cloud, central storage, and back-end data processing in a way older versions never attempted, modernizing the media production tool in a big way.

Top 10 Clean Energy Stocks To Watch For 2018: Novellus Systems Inc.(NVLS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Nivalis Therapeutics Inc (NASDAQ: NVLS) shares dropped 59 percent to $2.58 after the company reported it failed to demonstrate benefit in absolute change in predicted FEV1 or in Sweat Chloride Reduction at 12 weeks. The failed trial has prompted four Wall Street firms to downgrade the issue including Raymond James, Cowen, Baird and Stifel.

  • [By Paul Ausick]

    Nivalis Therapeutics Inc. (NASDAQ: NVLS) dropped 60% on Tuesday to post a new 52-week low of $2.50 after closing at $6.25 on Monday. The stock’s 52-week high is $9.45. Volume of about 4.2million was about 60 times the daily average of around 75,000 shares. The company reported a failed mid-stage trial on its treatment for cystic fibrosis.

  • [By Chris Lange]

    Nivalis Therapeutics, Inc. (NASDAQ: NVLS) is watching its shares crumble on Tuesday after the company gave an update on its mid-stage Cystic Fibrosis (CF) trial. Specifically, the company announced topline results from the its Phase 2 trial evaluating the efficacy and safety of two doses of cavosonstat, in adult patients with CF who had two copies of the F508del-CFTR mutation and were being treated with Orkambi.

Top 10 Clean Energy Stocks To Watch For 2018: Sandstorm Gold Ltd(SAND )

Advisors’ Opinion:

  • [By Rich Duprey]

    Sandstorm Gold (NYSEMKT:SAND) has outperformed the precious metal itself over the past year, with shares rising 35% year to date. Last month it reported third-quarter profits of $7 million, a big U-turn from 2015, when it suffered losses of $5.5 million. In fact, its entire operation was doing better with greater production: lower cash costs, but higher cash margins; and greater operating cash flows, all of which allowed it to pay down its revolving credit facility. That means it has no bank debt and its entire $110 million revolving credit facility is available to make acquisitions.

Top 10 Clean Energy Stocks To Watch For 2018: Viking Therapeutics, Inc.(VKTX)

Advisors’ Opinion:

  • [By Lisa Levin]

     

    Losers
    DBV Technologies SA – ADR (NASDAQ: DBVT) shares tumbled 50.6 percent to $23.73 after the company disclosed that its peanut allergy trial failed to meet primary endpoint.
    Connecture Inc (NASDAQ: CNXR) shares declined 40.8 percent to $0.290. Connecture reported that it will voluntarily delist from the NASDAQ for OTCQX Market.
    Walter Investment Management Corp (NYSE: WAC) slipped 19.2 percent to $0.410. On Friday, Walter Investment Management disclosed that it has reached an agreement with term lenders and senior noteholders on financial restructuring.
    Eldorado Gold Corp (USA) (NYSE: EGO) shares dropped 15.9 percent to $1.83. Eldorado Gold lowered its production guidance for its Kisladag operation.
    Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) shares fell 15.4 percent to $1.04.
    Future Fintech Group Inc (NASDAQ: FTFT) dropped 13.6 percent to $1.53. Future FinTech reported filing of proxy statement, including proposal for corporate restructuring.
    Concordia International Corp (NASDAQ: CXRX) shares fell 12.3 percent to $0.500 after dipping 38.71 percent on Friday.
    Aemetis Inc (NASDAQ: AMTX) shares declined 11.3 percent to $0.550
    OncoSec Medical Inc (NASDAQ: ONCS) dipped 10.5 percent to $1.12. OncoSec reported a $7.1 million registered direct at-the-market offering at a price of $1.34375 per share.
    Evoke Pharma Inc (NASDAQ: EVOK) shares fell 10.35 percent to $3.08 after the company disclosed 'positive' topline results from comparative exposure pharmacokinetic study for Gimoti.
    Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) shares dropped 9.4 percent to $11.60 as the company disclosed Phase 2 interim 24-week data with pegylated interferon lambda in Hepatitis Delta Virus infection at the American Association for the Study of Liver Diseases Meeting.
    Viking Therapeutics Inc (NASDAQ: VKTX) shares slipped 6.6 percent to $2.80. Viking Therapeutics presented results from proof-of-concept study of VK0214 in in vivo

  • [By Lisa Levin]

    Viking Therapeutics Inc (NASDAQ: VKTX) shares dropped 39 percent to $1.17 after the company priced 7.5 million share offering at $1.25 per share.

  • [By William Romov]

    Currently trading at $4.52 per share, Viking Therapeutics Inc. (Nasdaq: VKTX) develops drugs to treat fatty liver disease and post-hip surgery rehabilitation. It has the highest share price of the penny stocks on our list today.

Top 10 Clean Energy Stocks To Watch For 2018: Energy XXI Ltd.(EXXI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Energy XXI Ltd (NASDAQ: EXXI) were down 72 percent to $0.181 after the company announced that it and some of its subsidiaries have entered into a Restructuring Support Agreement (RSA) with holders of more than 63 percent of its secured second lien 11.0 percent notes. Energy XXI added that in order to implement the terms of the RSA, it has commenced cases under Chapter 11 of the Bankruptcy Code.

Top 10 Clean Energy Stocks To Watch For 2018: Sigma Designs, Inc.(SIGM)

Advisors’ Opinion:

  • [By Lisa Levin]

    Sigma Designs Inc (NASDAQ: SIGM) shares dropped 30 percent to $5.43. Sigma Designs reported fiscal third-quarter net income of $221,000 on revenue of $62.7 million.

  • [By Lisa Levin]

    Gainers

    Pyxis Tankers Inc. (NYSE: PXS) rose 47.48 percent to $$5.56, after the company announced it has entered into a definitive securities purchase agreement with a group of investors, which will result in gross proceeds of $4.8 million.
    Sigma Designs Inc (NASDAQ: SIGM) rose 22.77 percent to $6.88. Silicon Laboratories (NASDAQ: SLAB) announced plans to buy Sigma Designs for $7.05 per share in cash.
    Steadymed Ltd (NASDAQ: STDY) rose 19.35 percent to $3.70, after the company reported that no clinical trials were required for Trevyent and that the FDA had agreed to the pathway for the drug candidate's NDA resubmission.
    Iteris, Inc. (NASDAQ: ITI) rose 15.73 percent to $7.06. Earlier in the week, Zacks Investment Research had upgraded the company from "Sell" to "Hold".
    Science Applications International Corp (NYSE: SAIC) rose 13.71 percent to $85.77 as the company reported better-than-expected earnings for its third quarter.
    Technical Communications Corporation (NASDAQ: TCCO) rose 12.41 percent to $6.07, after having risen sharply in pre-marketing trading.
    Radius Health, Inc. (NASDAQ: RDUS) rose 12.41 percent to $30.81 after the company provided an update on data from the Phase 1 005 clinical study of elacestrant in patients with estrogen receptor positive breast cancer during the 2017 San Antonio Breast Cancer Symposium.
    ForeScout Technologies, Inc. (NASDAQ: FSCT) rose 12.32 percent to $25.80 after the company reported its third quarter financial results.
    Prana Biotechnology Limited (NASDAQ: PRAN) rose 11.36 percent to $3.43, as the company announced a research collaboration with Takeda Pharmaceuticals to study the ability of movement disorders compound, PBT434 to slow or prevent neurodegeneration of the gastrointestinal system.
    Catalyst Biosciences, Inc. (NASDAQ: CBIO) rose 10.49 percent to $7.90 as the company announced the appointment of Arwa Shurrab and Jamie Ellen Siegel in its clinical hemophilia

  • [By Paul Ausick]

    Sigma Designs Inc. (NASDAQ: SIGM) dropped about 34% on Wednesday to post a new 52-week low of $5.20 against a 52-week high of $8.60 and a Tuesday close of $7.75. Volume of about 6.2 million was about 25 times the daily average of around 280,000. The company reported so-so earnings on Tuesday and the stock was downgraded and price targets lowered by several analysts.

Top 10 Clean Energy Stocks To Watch For 2018: Zimmer Biomet Holdings, Inc.(ZBH)

Advisors’ Opinion:

  • [By Keith Speights]

    The three top dividend stocks in the dentistry industry are Patterson Companies (NASDAQ:PDCO), Zimmer Biomet Holdings (NYSE:ZBH), and Danaher (NYSE:DHR). But two of these, Zimmer Biomet and Danaher, pay out only small dividends.

  • [By WWW.GURUFOCUS.COM]

    For the details of Focused Investors LLC’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Focused+Investors+LLC

    These are the top 5 holdings of Focused Investors LLCZimmer Biomet Holdings Inc (ZBH) – 1,433,300 shares, 6.32% of the total portfolio. Shares added by 23.22%CVS Health Corp (CVS) – 2,120,700 shares, 6.01% of the total portfolio. Shares added by 19.73%Johnson & Johnson (JNJ) – 1,285,900 shares, 5.78% of the total portfolio. Shares reduced by 0.67%American Express Co (AXP) – 1,990,300 shares, 5.68% of the total portfolio. Shares reduced by 0.33%Anthem Inc (ANTM) – 944,800 shares, 5.64% of the total portfolio. Sh

Top 10 Clean Energy Stocks To Watch For 2018: Federated Investors, Inc.(FII)

Advisors’ Opinion:

  • [By Gregg Greenberg]

     Stocks of Federated Investors (FII) fell approximately 9% in 2015, yet Oja expects a big turnaround in 2016, once again due to the prospect of higher rates ahead. 

     

    "The money market fund business, which is unprofitable now, should become more profitable as rates rise because Federated has to reimburse for the servicing fees for these funds," said Oja, who also admires the fund company’s 3.5% dividend yield. 

     

    Oja added that Federated also has a "good core business of equity and fixed-income asset management." 

Top 10 Clean Energy Stocks To Watch For 2018: DAVIDsTEA Inc.(DTEA)

Advisors’ Opinion:

  • [By Monica Gerson]

    DavidsTea Inc (NASDAQ: DTEA) is expected to post its quarterly earnings at $0.43 per share on revenue of $71.74 million.

    SemiLEDs Corporation (NASDAQ: LEDS) is estimated to post its quarterly earnings.

most popular stocks to invest in

Americans 65 years and older may not have as many job-related costs, such as commuting to an office or work clothes, but they still spend plenty, according to data from the Bureau of Labor Statistics.

Housing was their greatest expense, at more than $15,500 a year (and about a 35% share of the household budget). Transportation accounted for nearly $7,000. Cash contributions, such as donations and child support, was more than $2,000, the data showed.

most popular stocks to invest in: Pershing Gold Corporation(PGLC)

Advisors’ Opinion:

  • [By Sara Cornell]

    Leading the way is CEO Edward Karr. As a founder of Pershing Gold Corp (NASDAQ:PGLC), he currently serves on their Board of Directors, and has been active in the natural resource industry for many years. With a background in finance and investment banking, Karr is credited with raising capital to begin operations at US Gold Corp, and establishing financing for both the operational and exploration sides of the company.

most popular stocks to invest in: Atlantia S.p.A. (ATASF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Atlantia (ATASF) (AT.IM), Eiffage (OTCPK:EFGSY) (FGR.FP), Ferrovial (OTC:FRRVF) (FER.SM), Albertis (OTC:ABFOF) (ABE.SM) and Vinci (OTCPK:VCISF) (DG.FP)

most popular stocks to invest in: Viking Therapeutics, Inc.(VKTX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Viking Therapeutics Inc (NASDAQ: VKTX) shares dropped 39 percent to $1.17 after the company priced 7.5 million share offering at $1.25 per share.

  • [By William Romov]

    Currently trading at $4.52 per share, Viking Therapeutics Inc. (Nasdaq: VKTX) develops drugs to treat fatty liver disease and post-hip surgery rehabilitation. It has the highest share price of the penny stocks on our list today.

  • [By Lisa Levin]

     

    Losers
    DBV Technologies SA – ADR (NASDAQ: DBVT) shares tumbled 50.6 percent to $23.73 after the company disclosed that its peanut allergy trial failed to meet primary endpoint.
    Connecture Inc (NASDAQ: CNXR) shares declined 40.8 percent to $0.290. Connecture reported that it will voluntarily delist from the NASDAQ for OTCQX Market.
    Walter Investment Management Corp (NYSE: WAC) slipped 19.2 percent to $0.410. On Friday, Walter Investment Management disclosed that it has reached an agreement with term lenders and senior noteholders on financial restructuring.
    Eldorado Gold Corp (USA) (NYSE: EGO) shares dropped 15.9 percent to $1.83. Eldorado Gold lowered its production guidance for its Kisladag operation.
    Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) shares fell 15.4 percent to $1.04.
    Future Fintech Group Inc (NASDAQ: FTFT) dropped 13.6 percent to $1.53. Future FinTech reported filing of proxy statement, including proposal for corporate restructuring.
    Concordia International Corp (NASDAQ: CXRX) shares fell 12.3 percent to $0.500 after dipping 38.71 percent on Friday.
    Aemetis Inc (NASDAQ: AMTX) shares declined 11.3 percent to $0.550
    OncoSec Medical Inc (NASDAQ: ONCS) dipped 10.5 percent to $1.12. OncoSec reported a $7.1 million registered direct at-the-market offering at a price of $1.34375 per share.
    Evoke Pharma Inc (NASDAQ: EVOK) shares fell 10.35 percent to $3.08 after the company disclosed 'positive' topline results from comparative exposure pharmacokinetic study for Gimoti.
    Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) shares dropped 9.4 percent to $11.60 as the company disclosed Phase 2 interim 24-week data with pegylated interferon lambda in Hepatitis Delta Virus infection at the American Association for the Study of Liver Diseases Meeting.
    Viking Therapeutics Inc (NASDAQ: VKTX) shares slipped 6.6 percent to $2.80. Viking Therapeutics presented results from proof-of-concept study of VK0214 in in vivo

most popular stocks to invest in: Huntsman Corporation(HUN)

Advisors’ Opinion:

  • [By Paul Ausick]

    Venator Materials PLC is a maker of titanium dioxide pigments and additives. The company is being spun out of Huntsman Corp. (NYSE: HUN) and plans to offer 22.7 million shares in an expected price range of $20 to $21, raising $465 million at an implied market cap of $2.18 billion. Underwriters include Citi, Goldman Sachs, BofA/Merrill Lynch, J.P. Morgan, Barclays, Deutsche Bank, UBS Investment Bank, RBC Capital Markets, Moelis & Company, HSBC Corp., Nomura Securities, SunTrust Robinson Humphrey, Academy Securities, and Commerzbank Capital. Shares are scheduled to price Wednesday and begin trading Thursday on the New York Stock Exchange under the ticker symbol VNTR.

  • [By Lee Jackson]

    Huntsman Corp. (NYSE: HUN) had its executive chairman selling stock last week. Jon Huntsman parted with 600,000 shares, and the share priceranged from $17.25 to $17.27. The total for the trade was posted at $10 million.The company manufactures and sells differentiated organic and inorganic chemical products worldwide. The stock traded Friday at $18.10, so some left on that table as well.

most popular stocks to invest in: Camping World Holdings, Inc. (CWH)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Camping World's (NYSE: CWH) analyst quiet period has ended. So far, it has received coverage form four analysts.

    Sell-Side's Most Noteworthy Calls
    Morgan Stanley downgraded Juniper (NYSE: JNPR) to Underweight.
    Guggenheim downgraded MasterCard (NYSE: MA) to Neutral.
    Imperial Capital upgraded Allegion (NYSE: ALLE) to Outperform.
    Summit Redstone upgraded VMware (NYSE: VMW) to Buy.
    Oppenheimer started Twilio (NYSE: TWLO) at Outperform.
    Deal Talk

    Cipher Pharmaceuticals (NASDAQ: CPHR) is said to have hired an investment bank to explore strategic alternatives, according to sources as reported by Reuters on Monday. The sources said a potential sale of the Canada-based company is being considered. Cipher declined comment on the report.

  • [By Elizabeth Balboa]

    Supply could come from any number of industry players, including Winnebago Industries, Inc. (NYSE: WGO), Thor Industries, Inc. (NYSE: THO), Polaris Industries Inc. (NYSE: PII) and Camping World Holdings Inc (NYSE: CWH). However, whether it comes from existing inventory and whether suppliers can meet the demand are yet to be seen.

Your Daily Pharma Scoop: Biogen Setback, Ironwood Commences Trial, Vtv Signs 2 Deals

Analysis of top Seeking Alpha coverage: Biogen

Today we will focus on Biogens (BIIB) announcement regarding BAN2401, the companys Alzheimers candidate in mid-stage study.

Biogen shares dropped more than 3% on Thursday after the company said that an Independent Data Monitoring Committee determined that the Phase 2 study evaluating BAN2401 in patients with early or mild Alzheimers disease (AD) failed to meet the criteria for success at the end of 12 months. The drug is being co-developed with Eisai.

The news highlights the major concern we have had with Biogen. Two years ago, the company announced a restructuring and shifted its focus towards neurology, with Alzheimers being a key area. But the high failure rate of Alzheimers drugs makes this a very risky strategy. It must be noted that the failure of BAN2401 has no bearing on Biogens lead candidate in AD, aducanumab. The companys lead Alzheimers candidate has a different mechanism of action. However, the effectiveness of aducanumab is still to be tested in a large population. And given the high failure rate with Alzheimers candidate, we are cautious on Biogen.

Another concern, which has been addressed partly, is Biogens multiple sclerosis (MS) franchise. We have already discussed the issues with the MS space in several articles, which can be found here, here and here. To briefly recap though, the MS space has become extremely crowded and faces generic competition. The approval of Copaxone 40 mg generic means that there is now already a generic in the MS market. And it comes at a time when major MS players have already been under the scanner for pricing MS drugs. Remember that much of the sales growth in the MS space in recent years has been achieved through price increases rather than volume growth.

Coming back to Biogens MS franchise, the approval of generic Copaxone does put pressure on pricing although BIIBs Tecfidera, the biggest MS drug in the franchise, is an oral therapy. But Tecfidera has problems of its own, although none of it immediate. As we noted in earlier articles, the oral MS therapy space faces potential generic competition from 2020 onwards if patents on Novartis (NVS) MS drug Gilenya are invalidated. If the patents are invalidated, then generics could knock off a significant portion of Tecfidera sales. The problem for Biogen is that its MS pipeline is extremely thin, with not much to offset the loss of these sales.

Biogen has addressed a more immediate problem, the threat to Tecfidera from ALKS 8700. The company recently signed a global licensing agreement for ALKS 8700, which potentially has a better safety and tolerability profile compared to Tecfidera. But the licensing agreement is more of an insurance than an aggressive deal. It must be noted that the deal has been signed on favorable terms but it does not add much to Biogens MS franchise.

While Thursdays development is not a major setback for Biogen, we remain cautious on the stock because of the overreliance on aducanumabs success. We continue to see Gilead (GILD) and Celgene (CELG) as more favorable bets in the large cap biopharma space.

Stocks in the news: Analysis of BLRX, SMMT, IRWD, CELG

BioLineRx (BLRX) announced that it has commenced a Phase 3 clinical trial, GENESIS, to evaluate L-8040 for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients.

Co Name

BioLineRx

Ticker

BLRX

Focus Area

clinical-stage therapeutics to address unmet needs

Price (last close)

$1.12

52-week high

$1.38

52-week low

$0.80

Diff. from 52-week low

40%

Market Cap

118.08M

Enterprise Value

61.88M

Cash (mrq)

55.01M

Debt (mrq)

273K

Analysis: The Phase 3 study will compare the combination of BL-8040 and granulocyte colony-stimulating factor (G-CSF) to placebo plus G-CSF in ~180 subjects. The primary endpoint will be the proportion of patients who mobilize a minimum number of CD34+ cells [6.0 x 10 (6)] with up the two apheresis sessions after a single administration of BL-8040 and G-CSF. The estimated trial completion date is September 2019.

Summit Therapeutics (SMMT) announced that it signed an exclusive license and commercialisation agreement granting Eurofarma Laborat贸rios SA rights in Latin America to ridinilazole, currently in development for the treatment of Clostridium difficile infection (CDI).

Co Name

Summit Therapeutics

Ticker

SMMT

Focus Area

genetic and infectious diseases

Price (last close)

$10.58

52-week high

$16.86

52-week low

$7.95

Diff. from 52-week low

33.08%

Market Cap

148.6M

Enterprise Value

85.87M

Cash (mrq)

42.37M

Debt (mrq)

n/a

Analysis: According to the terms of the agreement, Summit will receive an upfront payment of $2.5 million. The company is also entitled milestone payments of up to $25 million. As part of the agreement, Summit will also receive product supply transfer payments in high single digit to low double-digit percentage of net sales.

Ironwood (IRWD) announced that it has commenced a Phase 2 trial, STRONG-SCD, evaluating IW-1701 in patients with sickle cell disease (SCD).

Co Name

Ironwood Pharmaceuticals, Inc.

Ticker

IRWD

Focus Area

Therapeutics, IBS

Price (last close)

$15.85

52-week high

$19.94

52-week low

$13.43

Diff. from 52-week low

18.02%

Market Cap

2.37B

Enterprise Value

2.55B

Cash (mrq)

225.42M

Debt (mrq)

396.34M

Analysis: This will be a randomized, placebo-controlled study. The company plans to enroll 88 subjects in the study, who will remain on their current treatment regimens for the duration of the trial. The primary endpoint of the trial is safety and tolerability. Secondary outcome measures include efficacy. The estimated trial completion date is July 2019.

Celgene (CELG) announced that a Phase 3 trial evaluating its REVLIMID (lenalidomide) plus Biogen’s (BIIB) RITUXAN (rituximab) in treatment-naive follicular lymphoma (FL) patients failed to demonstrate a treatment benefit over standard-of-care (SOC) therapy.

Co Name

Celgene Corporation

Ticker

CELG

Focus Area

cancer and inflammatory diseases

Price (last close)

$107.88

52-week high

$147.17

52-week low

$94.55

Diff. from 52-week low

14.1%

Market Cap

84.94B

Enterprise Value

87.56B

Cash (mrq)

11.79B

Debt (mrq)

14.28B

Analysis: The Phase 3 study, RELEVANCE, evaluated REVLIMID/RITUXAN (RxR) followed by RxR maintenance compared to REVLIMID plus chemotherapy (R-CHOP or R-CVP). The RxR arm failed failed to show statistically valid superiority over SOC as determined by complete response at week 120 or progression-free survival. The news has sent CELG shares down, but we would not read too much into it. It has been a difficult year for CELG but we remain positive on the long-term prospects.

In other news

vTv Therapeutics (VTVT) announced that it has signed a license agreement with Huadong Medicine’s Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. granting it exclusive rights to develop, manufacture and commercialize vTv’s GLP-1R agonist program in China, Hong Kong and 12 other Asian countries (ex. Japan). The company has also signed an agreement with Reneo Pharmaceuticals under which Reneo has secured exclusive global rights to vTvs selective peroxisome proliferator-activated receptor delta (PPAR-delta) program. As part of the deal, vTv will receive an upfront payment, milestones and royalties on net sales. The financial terms of the deal though have not been made public.

Gemphire Therapeutics (GEMP) announced that it launched a clinical program to develop emcabene as a treatment for NASH/nonalcoholic fatty liver disease (NAFLD).

Johnson & Johnsons (JNJ) subsidiary Janssen announced that the FDA has granted its apalutamide, a next-generation oral androgen receptor inhibitor, for Priority Review for the treatment of non-metastatic castration-resistant prostate cancer.

Biohaven (BHVN) announced that it has commenced enrollment in its Phase 2/3 trial evaluating the efficacy and safety of trigriluzole in patients with obsessive-compulsive disorder (OCD).

Jazz Pharmaceuticals (JAZZ) announced that it has filed U.S. marketing application for its Orphan Drug-designated olriamfetol (JZP-110) for the treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea.

Acasti Pharma (ACST) announced public offering of 9.9 million shares of common stock and accompanying warrants to purchase up to 8.9 million shares of common stock for $1.01 per share and warrant. Net proceeds from the offering will help fund the continued development of CaPre, expansion of business development activities, working capital and general corporate purposes.

Analyst Ratings

Company

Analyst

Action

Rating

Target

Avisol Analysis

ABIOMED (ABMD)

Jefferies Group

Raises Target

Buy

$208.00 -> $220.00

AEterna Zentaris (AEZS)

Maxim Group

Set Price Target

Buy

$4.00

Yes

Axovant Sciences (AXON)

Jefferies Group

Downgrades

Buy -> Hold

$6.00

Yes

Biogen (BIIB)

Mizuho

Set Price Target

Buy

$400.00

Yes

Bioline RX (BLRX)

HC Wainwright

Set Price Target

Buy

$4.00

Bioline RX (BLRX)

Oppenheimer

Initiates

Buy

$3.00

bluebird bio (BLUE)

CIBC

Initiates

Market Perform -> Market Perform

Yes

Catalyst Pharmaceuticals (CPRX)

HC Wainwright

Reiterates

Buy

$6.00

Crispr Therapeutics (CRSP)

Oppenheimer

Reiterates

Hold

Cardiovascular Systems (CSII)

William Blair

Initiates

Hold

Exelixis (EXEL)

SunTrust Banks

Reiterates

Buy

$38.00

Yes

Gilead Sciences (GILD)

Oppenheimer

Reiterates

Hold

Yes

Intercept Pharmaceuticals (ICPT)

Citigroup

Set Price Target

Hold

$74.00

Yes

Invacare (IVC)

KeyCorp

Reiterates

Buy

$20.00

La Jolla Pharmaceutical (LJPC)

HC Wainwright

Initiates

Buy -> Buy

$62.00

Medtronic (MDT)

Oppenheimer

Reiterates

Buy

MEI Pharma (MEIP)

Cann

Reiterates

Buy

$6.50

MEI Pharma (MEIP)

Oppenheimer

Set Price Target

Buy

$7.00

Mirati Therapeutics (MRTX)

Cowen

Initiates

Outperform

Aratana Therapeutics (PETX)

HC Wainwright

Set Price Target

Buy

$10.00

Yes

Rigel Pharmaceuticals (RIGL)

Piper Jaffray Companies

Reiterates

Overweight -> Overweight

$6.00

Soligenix (SNGX)

Maxim Group

Set Price Target

Buy

$5.00

Syros Pharmaceuticals (SYRS)

HC Wainwright

Reiterates

Hold

$10.00

Verastem (VSTM)

Oppenheimer

Set Price Target

Buy

$13.00

GILD is in Avisol portfolio.

Insider Sales

Adamas Pharmaceuticals Inc (ADMS): CBO, GC, Compliance Officer Rhodes Jennifer J disposed 440 shares for $14,212.

Concert Pharmaceuticals, Inc. (CNCE): 10% shareholders Bvf Partners disposed 1282856 shares (91% of their holding) for $34,188,112.

Illumina Inc (ILMN): Director Flatley Jay T disposed 20000 shares for $4,309,502.

Ligand Pharmaceuticals Inc (LGND): Director Sabba Stephen L disposed 925 shares for $126,956.

Regenxbio Inc. (RGNX): President & CEO Mills Kenneth T disposed 10000 shares for $317,500.

Insider Acquisitions

Marijuana Co of America, Inc. (OTCPK:MCOA): President & 10% shareholder Steinberg Donald J acquired 6700000 shares for $252,656.

Mannkind Corp (MNKD): Corp VP, Chief People Officer Tross Stuart A acquired 39840 shares for $100,397.

Secondary Offerings

Company

Stock Offering

Price Offering

Vistagen Therapeutics (NASDAQ:VTGN)

$15 Million

$1.25/Share

Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

$20 Million

$8.50/Share

Fibrocell Science Inc. (NASDAQ:FCSC)

$5.9 Million

$0.77/Share

Viking Therapeutics Inc. (NASDAQ:VKTX)

$12.8 Million

$2.50/Share

Total Pharma Tracker subscribers get the full version of daily pharma scoop with actionable ideas a day earlier. A recent idea that gave spectacular returns to our subscribers was AEZS.

Subscribe to the TPT service to also get detailed research reports on stocks you own, or should own, up to a month earlier than non-subscribers.

Click here to SUBSCRIBE.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Editor’s Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.

SeekingAlphaAbout this article:ExpandAuthor payment: $35 + $0.01/page view. Authors of PRO articles receive a minimum guaranteed payment of $150-500.Tagged: Investing Ideas, Quick Picks & Lists, Healthcare, BiotechnologyWant to share your opinion on this article? Add a comment.Disagree with this article? Submit your own.To report a factual error in this article, click here